Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 380.00
Bid: 374.00
Ask: 386.00
Change: 0.00 (0.00%)
Spread: 12.00 (3.209%)
Open: 380.00
High: 380.00
Low: 380.00
Prev. Close: 380.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020

Mon, 11th Jan 2021 14:51

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Science Group PLC - Cambridge-based scientific consultancy services firm - Says it expects revenue for 2020 to soar 28% to GBP73 million from GBP57.2 million and for operating profit to beat its previously upgraded forecast of GBP10 million, up from GBP6.7 million in 2019. Says Finance Director Rebecca Archer will step down to take up a new role after completion of the 2020 results audit. Adds it has hired former Ted Baker interim finance director Sameet Vohra as chief financial officer designate.

----------

Rotala PLC - West Midlands-based bus operator - For financial 2020 ended November 30, expects to swing to pretax loss of GBP1.0 million from profit of GBP3.6 million the year before despite an increase in turnover to GBP76.0 million from GBP67.5 million. Blames the performance on Covid-19 lockdowns but notes the UK government grant package, the CBSSG Restart, helped its performance. However, it says the provisions of CBSSG Restart and the associated UK Government measures were designed to ensure it makes neither a profit nor a loss until the measures are terminated. As such, it expects to make neither a profit nor loss for financial 2021.

----------

InnovaDerma PLC - London-based beauty, personal care and life science products firm - Expects revenue for the six months ended December 31 to be around GBP4.1 million, down from GBP5.1 million the year prior, with UK sales declining due to a reduction in beauty category consumption amid the Covid-19 pandemic. Adds it has dismissed Joe Bayer from the role of chair effective immediately with existing Non-Executive Director Ross Andrews to replace him.

----------

W Resources PLC - London-based tungsten, tin and gold mining company with assets in Spain and Portugal - Draws down further GBP500,000 from its GBP4.0 million Atlas Capital Markets convertible bond facility, the second drawdown since the facility was secured in March 2020. This convertible bond tranche has a 5% coupon and 3-year term. The company will use the cash to advance the Regua mine development and provide additional working capital.

----------

AssetCo PLC - Middle East-focused provider of management and resources to the fire and emergency services - Says Aberdeen Asset Management Founder Martin Gilbert, Aberdeen's former global head of private markets Peter McKellar, various associates and funds managed by Toscafund Asset Management acquire a 29.8% stake at 475 pence per share. Following the receipt of regulatory approvals, Martin Gilbert and Peter McKellar will join the board as non-executive directors.

----------

MaxCyte Inc - Maryland-based cell and gene therapies firm - Inks a clinical and commercial licensing agreement with Myeloid Therapeutics to advance Myeloid's cell therapy programmes. Under the deal, Myeloid Therapeutics will obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte will receive development and approval milestones and sales-based payments, along with other licensing fees. No financial details were disclosed.

----------

Hutchison China Meditech Ltd - China-based biopharmaceutical company - Enters strategic partnership with Inmagene Biopharmaceuticals to further develop four novel preclinical drug candidatesfor the potential treatment of multiple immunological diseases. The companies will work together to move the drug candidates towards investigational new drug submission. If successful, Inmagene will then move the drug candidates through global clinical development. For each of the drug candidates, Chi-Med will be entitled to development milestones of up to USD95 million and up to USD135 million in commercial milestones as well as up to double-digit royalties upon commercialization.

----------

By Ife Taiwo; ifetaiwo@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 Dec 2021 15:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
23 Nov 2021 16:21

DIRECTOR DEALINGS: New MaxCyte chair buys USD220,000 in shares

DIRECTOR DEALINGS: New MaxCyte chair buys USD220,000 in shares

Read more
23 Nov 2021 15:25

Director dealings: Maxcyte chairman makes share purchase

(Sharecast News) - Maxcyte revealed on Tuesday that chairman Richard Douglas had acquired 20,000 ordinary shares in the AIM-listed cell-engineering company.

Read more
11 Nov 2021 21:26

TRADING UPDATES: iEnergizer and Volex post interim profit hikes

TRADING UPDATES: iEnergizer and Volex post interim profit hikes

Read more
11 Nov 2021 11:58

MaxCyte revenue jumps more than 50pc in third quarter

(Sharecast News) - Commercial cell engineering company MaxCyte reported total third quarter revenue of $10.1m in an update on Thursday, representing 50% growth compared to the same period in 2020.

Read more
3 Nov 2021 14:13

EXECUTIVE CHANGES: MaxCyte promotes to chair; Sanderson adds retailers

EXECUTIVE CHANGES: MaxCyte promotes to chair; Sanderson adds retailers

Read more
29 Oct 2021 21:20

TRADING UPDATES: Mattioli outlook promising; virus hits Grand Vision

TRADING UPDATES: Mattioli outlook promising; virus hits Grand Vision

Read more
28 Oct 2021 19:19

TRADING UPDATES: Hunting hurt by Ida; React revenue short of consensus

TRADING UPDATES: Hunting hurt by Ida; React revenue short of consensus

Read more
22 Oct 2021 16:03

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
1 Oct 2021 17:55

IN BRIEF: MaxCyte Chair Thompson to step down late October

IN BRIEF: MaxCyte Chair Thompson to step down late October

Read more
17 Sep 2021 17:50

IN BRIEF: MaxCyte to join Russell 2000 index in US on September 20

IN BRIEF: MaxCyte to join Russell 2000 index in US on September 20

Read more
14 Sep 2021 17:46

TRADING UPDATES: Strong annual results from Springfield, Fiske

TRADING UPDATES: Strong annual results from Springfield, Fiske

Read more
6 Sep 2021 15:58

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
9 Aug 2021 17:08

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

Read more
2 Aug 2021 21:22

IN BRIEF: MaxCyte underwriters exercise over-allotment option

IN BRIEF: MaxCyte underwriters exercise over-allotment option

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.